Articles
Chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL) are common hematologic malignancies that represent a significant burden to patients and to the healthcare system. In light of the morbidity, mortality, and quality-of-life challenges associated with CLL and NHL, there is a marked need for additional therapeutic options for patients with these malignancies. Read More ›
Lung cancer is the second most common cancer in the United States. In 2015, an estimated 221,200 new cases of lung cancer were diagnosed, representing 13.3% of all new cancer cases. Furthermore, lung cancer is the leading cause of cancer mortality in men and women, responsible for 27% of all cancer deaths, and claiming more lives than breast, colon, prostate, and ovarian cancers combined. Read More ›
The drugs included in this review were approved by the US Food and Drug Administration (FDA)
in 2015 and are grouped into the following categories. Read More ›
The number of oncology trials seeking new indications for new and known agents is continuing to grow at a fevered pitch. The fruition of this work is now being realized; in the past 12 months, there have been 36 hematology/oncology drug approvals, 18 of which involved new drug entities. Read More ›
Venetoclax (Venclexta) has been approved by the US Food and Drug Administration (FDA) for daily use in patients with chronic lymphocytic leukemia (CLL) who have 17p deletion, and had ≥1 prior therapies, according to an announcement by the agency. This drug is the first treatment that targets the B-cell lymphoma 2 protein, which is overexpressed in many patients with CLL. Read More ›
There were a number of areas where we asked the forecast panelists questions specifically regarding oncology, and how the changing environment might relate to oncology pharmacists. Read More ›
Defibrotide sodium (Defitelio) is now US Food and Drug Administration (FDA)-approved for children and adult patients with hepatic veno-occlusive disease (VOD) with added kidney or lung abnormalities following hematopoietic stem cell transplantation (HSCT). This drug is the first to be approved for patients with severe hepatic VOD. Read More ›
Immediate-release opioid analgesics will now require boxed warnings regarding the serious risks for abuse, addiction, overdose, neonatal opioid withdrawal syndrome (NOWS), and death associated with the drugs, according to an announcement by the US Food and Drug Administration (FDA). Read More ›
Crizotinib (Xalkori) has been approved for expanded use in patients with metastatic non−small-cell lung cancer (NSCLC) whose tumors have an ROS1 gene alteration, according to an announcement by the US Food and Drug Administration (FDA). The first and only approved treatment for this patient population, crizotinib blocks ROS1 protein activity in tumors, possibly preventing NSCLC from spreading. Read More ›
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Read More ›